（编辑 袁冠琳） 证券日报网讯 1月15日，东富龙在互动平台回答投资者提问时表示，公司加强研发团队和能力的建设， 对行业前沿技术进行前瞻性研究，强化与制药企业间的交流与研讨，携手为新的制药应用场景贡献力 量。 ...

（记者 张喜威） 东富龙（300171.SZ）1月8日在投资者互动平台表示，截至目前，公司未持有上海诺诚电器股份。 每经AI快讯，有投资者在投资者互动平台提问：公司持有多少上海诺诚电气股份，该公司早在2016 年，与新加坡A*STAR合作推出国内首款脑机接口＂脑复康＂，实现脑机交互关键技术突破。 ...

证券日报网讯 1月5日，东富龙在互动平台回答投资者提问时表示，公司参股的子公司可详见公司披露 的定期报告。2026年度，公司将持续关注并积极寻求新的外延成长机会，在充分考量业务布局、协同效 应、创新性及独特性的前提下，积极寻找合适的领域或者标的，力争实现内生与外延成长的协同发展。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯 1月5日，东富龙在互动平台回答投资者提问时表示，公司积极立足"提质增效"的主题， 发挥产品创新的技术优势，提升公司产品结合前沿技术的能力，进一步打造产品的差异化竞争优势，做 好为客户提供广泛服务的能力，为赢取优质订单奠定扎实基础，努力提升公司的盈利能力。 ...

资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日，公司主营业务涉及医用冻干机及冻干系统的研发、设计、生产、销售和服务。 主营业务收入构成为：制剂事业部44.92%，生物工艺事业部29.83%，工程事业部9.19%，食品事业部 9.16%，售后服务与配件6.81%，其他(补充)0.09%。 截至9月30日，东富龙股东户数3.14万，较上期减少2.14%；人均流通股17910股，较上期增加2.19%。 2025年1月-9月，东富龙实现营业收入37.04亿元，同比增长6.14%；归母净利润1.32亿元，同比减少 13.86%。 12月29日，东富龙跌0.06%，成交额1.00亿元。两融数据显示，当日东富龙获融资买入额851.76万元， 融资偿还926.74万元，融资净买入-74.99万元。截至12月29日，东富龙融资融券余额合计2.80亿元。 融资方面，东富龙当日融资买入851.76万元。当前融资余额2.79亿元，占流通市值的2.29%，融资余额 超过近一年50%分位水平，处于较高位。 融券方面，东富龙12月29日融券偿还200.00 ...

中信证券股份有限公司 保荐机构本次持续督导培训的工作过程中，公司积极予以配合，保证了培训 工作的有序进行，达到了良好效果。 三、本次持续督导培训的结论 关于东富龙科技集团股份有限公司 2025年度持续督导培训情况的报告 中信证券股份有限公司（以下简称"中信证券""保荐机构"）根据《深圳 证券交易所上市公司自律监管指引第 13 号——保荐业务》对东富龙科技集团股 份有限公司（以下简称"东富龙""公司"）进行了 2025 年度持续督导培训， 报告如下： 一、本次持续督导培训的基本情况 （一）保荐机构：中信证券股份有限公司 （六）培训人员：王天祺 （七）培训对象：公司董事、高级管理人员、部分中层以上管理人员以及公 司控股股东和实际控制人等相关人员 （八）培训内容：根据《深圳证券交易所创业板股票上市规则》以及《深圳 证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》等规则要 求，重点对上市公司募集资金使用、规范运作以及近期法律法规等方面进行了培 训。 二、上市公司的配合情况 （二）保荐代表人：赵洞天、王天祺 （三）协办人：牛瑞 （四）培训时间：2025 年 12 月 22 日 （五）培训地点：上海市闵 ...

Core Viewpoint - The pharmaceutical equipment industry is experiencing a recovery, with many listed companies showing a turning point in performance due to a resurgence in demand as the pharmaceutical sector enters an expansion phase [1][2][10]. Industry Recovery - The pharmaceutical equipment sector was previously in a downturn due to the global biopharmaceutical industry's cyclical decline, but by Q3 2025, most related companies have shown signs of recovery [2][12]. - The global capacity is entering an expansion phase, which is expected to significantly benefit the pharmaceutical equipment industry [1][15]. Company Performance - In Q3 2025, Chutian Technology reported revenues of 1.479 billion yuan and a net profit of 96.77 million yuan, with year-on-year growth of 10.17% in revenue and 192.50% in net profit [3][12]. - Dongfulong achieved revenues of 1.275 billion yuan and a net profit of 85.66 million yuan in Q3 2025, marking a significant improvement compared to the previous quarter [3][13]. - Despite a decline in revenue and net profit in the first half of 2025, Sensong International's new orders reached a historical high, driven by a surge in pharmaceutical contracts [4][14]. Contract Liabilities - Both Chutian Technology and Dongfulong have seen a continuous increase in contract liabilities, indicating a growing backlog of orders [4][13]. Capacity Expansion Plans - Major domestic companies like WuXi Biologics and Kangfang Biologics are set to initiate new capacity expansions in 2024, with significant increases in production capabilities [5][15]. - Internationally, multinational pharmaceutical companies are also advancing their global capacity layouts to enhance supply chain resilience, with substantial investments planned in the U.S. [5][16]. International Market Opportunities - The global pharmaceutical equipment market is projected to grow significantly, with domestic companies having substantial opportunities for international expansion [7][17]. - Domestic brands are increasingly competitive, with a notable shift towards local production capabilities, indicating a strong potential for import substitution [7][17]. Strategic Internationalization - Companies like Sensong International are leveraging their long-term technological expertise to enhance their international presence, aiming to capture new orders amid the ongoing industry transition [8][18]. - Dongfulong and Chutian Technology are actively expanding their overseas operations, with Dongfulong already achieving significant sales in international markets [9][19].

Market Overview - The medical device sector increased by 1.35% on December 25, with Sainuo Medical leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Performers - Sainuo Medical (688108) closed at 20.43, up 14.90%, with a trading volume of 609,800 shares and a transaction value of 1.22 billion [1] - Jinhao Medical (920925) closed at 33.03, up 12.81%, with a trading volume of 38,400 shares [1] - Mailland (688273) closed at 40.38, up 12.07%, with a trading volume of 54,800 shares [1] - Tianchen Medical (688013) closed at 52.94, up 11.10%, with a trading volume of 31,200 shares [1] - Xiangyu Medical (688626) closed at 57.47, up 6.80%, with a trading volume of 53,400 shares [1] Underperformers - C Jianxin (688805) closed at 53.31, down 8.28%, with a trading volume of 142,100 shares and a transaction value of 754 million [2] - Tianyi Medical (301097) closed at 51.89, down 5.43%, with a trading volume of 18,800 shares [2] - Hualan Co. (301093) closed at 49.54, down 2.75%, with a trading volume of 39,000 shares [2] Capital Flow - The medical device sector saw a net inflow of 137 million from institutional investors, while retail investors experienced a net inflow of 65.58 million [2] - The sector's main funds saw a net outflow of 203 million from speculative funds [2] Individual Stock Capital Flow - Sainuo Medical had a net inflow of 117 million from main funds, but a net outflow of 98.09 million from retail investors [3] - Zhend Medical (603301) had a net inflow of 85.32 million from main funds, with a net outflow of 76.17 million from retail investors [3] - Huakang Clean (301235) had a net inflow of 65.37 million from main funds, with a net outflow of 64.32 million from retail investors [3]

（文章来源：证券日报） 证券日报网讯 12月19日，东富龙发布公告称，公司第六届董事会第二十次（临时）会议审议通过《关 于部分募投项目延期的议案》。 ...

每经AI快讯，东富龙（SZ 300171，收盘价：15.37元）12月19日晚间发布公告称，公司第六届第二十次 董事会临时会议于2025年12月19日以通讯表决方式召开。会议审议了《关于部分募投项目延期的议案》 等文件。 每经头条（nbdtoutiao）——海南封关首日直击：为中国探路，全球最大自贸港如何重塑开放边界？ （记者 贾运可） 2024年1至12月份，东富龙的营业收入构成为：专用设备制造业占比99.84%，服务占比0.16%。 截至发稿，东富龙市值为118亿元。 ...